Abelacimab

Summary

Abelacimab (CHEMBL4650369) is a phase-3 clinical-stage antibody targeting F11; indicated across 2 conditions including atrial fibrillation and venous thromboembolism.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (F11)
• Indications: 2 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650369
Name	Abelacimab
Type	Antibody
Max phase	3

Also known as: Abelacimab, ABELACIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
F11	coagulation factor XI	Inhibition	11.33	0.2%	P03951

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): F11.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
R-HSA-140837	1	F11
Defective F9 activation	1	F11
Regulation of clotting cascade	1	F11
Amplification and propagation of coagulation cascade	1	F11
FXIIa, PKa-dependent activation of coagulation pathway	1	F11

Dominant GO biological processes

GO term	Targets
blood coagulation	1
plasminogen activation	1
positive regulation of fibrinolysis	1
proteolysis	1
hemostasis	1
regulation of blood coagulation	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atrial fibrillation	3	MONDO:0004981	EFO:0000275
venous thromboembolism	3	MONDO:0005399	EFO:0004286

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05712200	PHASE3	RECRUITING	Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05171049	PHASE3	TERMINATED	A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171075	PHASE3	TERMINATED	A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT04755283	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

4 molecules share ≥1 primary target. Top 4 by shared-target count:

Molecule	Source	Status	Shared targets
MELAGATRAN	ChEMBL	Phase 4 (approved)	F11
MILVEXIAN	ChEMBL	Phase 3	F11
FRUNEXIAN	ChEMBL	Phase 2	F11
Amiloride	PubChem	Approved	F11